Hostname: page-component-cd9895bd7-gbm5v Total loading time: 0 Render date: 2024-12-23T23:32:25.006Z Has data issue: false hasContentIssue false
  • English
  • Français

Terapia neuroléptica a dosis bajas y efectos secundarios extrapiramidales en esquizofrenia: un análisis del tamaño del efecto

Published online by Cambridge University Press:  12 May 2020

C. Barbui  and
B. Saraceno
C. Barbui
Affiliation:
Laboratorio de Epidemiología y Psiquiatría Social, Instituto “Mario Negri” para la Investigación Farmacológica, Milán, Italia
B. Saraceno
Affiliation:
Laboratorio de Epidemiología y Psiquiatría Social, Instituto “Mario Negri” para la Investigación Farmacológica, Milán, Italia
Get access

Resumen

Se realizó un metaanálisis de los trabajos publicados para cuantificar la eficacia de la terapia neuroléptica a dosis bajas en la reducción de los efectos secundarios extrapiramidales en pacientes esquizofrénicos. Un régimen de dosis bajas entre 50- 100 mg de equivalentes de clorpromacina, en comparación con un régimen de dosis estándar entre 200-500 mg, redujo los efectos secundarios extrapiramidales en un 0,30 (± 0,12) de desviación típica, lo que sólo es un efecto limitado.

Keywords

neurolépticodosis bajasefectos secundarios
Type
Comunicación breve
Information
European Psychiatry (Ed. Española) , Volume 4 , Issue 5 , July 1997 , pp. 323 - 326
Copyright
Copyright © European Psychiatric Association 1997

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

Barbui C, Saraceno B. Low-dose neuroleptic therapy and extrapyramidal side effects in schizophrenia: an effect size analysis. Eur Psychiatry 1996; 11: 412-415

References

Bibliografia

Baldessarini, RJCohen, BMTeicher, M. Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch Gen Psychiatry 1988; 45: 79–91.CrossRefGoogle ScholarPubMed
Bangert-Drowns, RL. Review of developments in metaanalytic method. Psychol Bull 1986; 99: 388-99.CrossRefGoogle Scholar
Barber, JPLuborsky, LB. Psychotherapy research: issues to consider in planning a study. In: Hsu, LKJHersen, M, eds. Research in Psychiatry. Issues, Strategies and Methods. New York: Plenum, 1992; 331-58.CrossRefGoogle Scholar
Barbui, C. Terapia a lungo termine delle psicosi. neurolettici ed interventi psicosociali. Lett Perc Bibliogr Psichiat 1995; XIX: 1–36.Google Scholar
Barbui, CSaraceno, BLiberad, AGarattini, S. Low-dose neuroleptic therapy and relapse in schizophrenia: meta-analysis of randomized controlled triais. Eur Psychiatry (in press).Google Scholar
Bollini, PPampallano, SOrza, MJAdams, MEChalmers, TC. Antipsychotic drugs: is more worse? A metaanalysis of the published randomized controlled triais. Psychol Med 1994; 24: 307-16.CrossRefGoogle Scholar
Bumett, PLGalletly, CAMoyle, RClark, CR. Low-dose depot medication in schizophrenia. Schizophren Bull 1993; 19: 155-64.Google Scholar
Cohen, J. Statistical Power Analysis of the Social Sciences, 2nd edn. New York: Academica Press, 1977.Google Scholar
Gilber, PLHarris, MJMcAdams, LAJeste, DV. Neuroleptic withdrawal in schizophrenic patients. A review of the literature. Arch Gen Psychiatry 1995; 52: 173-88.CrossRefGoogle Scholar
Hasselblad, VMosteller, F, Littenberg B et al. A survey of current problems in meta-analysis. Med Care 1995; 33: 202-20.CrossRefGoogle Scholar
Hogarty, GEMcEvoy, JP, Munetz M et al. Dose of fluphenazine, familial expressed emotion, and outcome in schizophrenia. Arch Gen Psychatry 1988; 45: 797–805.CrossRefGoogle Scholar
Inderbitzin, LBLewine, RRJ, Scheller-Gilkey G et al. A double-blind dose-reduction trial of fluphenazine decanoate for chronic, unstable schizophrenic patients. Am J Psychiatry 1994; 151: 1753–9.Google Scholar
Johnson, DAWLudlow, JMStreet, KTaylor, RDW. Double- blind comparison of half-dose and standard-dose flupenthixol decanoate in the maintenance treatment of stabilized out-patients with schizophrenia. Br J Psychiatry 1987; 151: 634-8.CrossRefGoogle Scholar
Kane, JMRifkin, AWoerner, MReardon, GSarantakos, SSchiebel, DRamos-Lorenzi, J. Low-dose neuroleptic treatment of outpatient schizophrenics. Arch Gen Psychiatry 1983; 40: 893-6.CrossRefGoogle ScholarPubMed
Marder, SRVan Putten, TMintz, J et al. Costs and benefits of two doses of fluphenazine. Arch Gen Psychiatry 1984; 41: 1025–9.CrossRefGoogle Scholar
Marder, SRVan Putten, TMintz, JLebell, MMcKenzie, J, May PRA. Low-and conventional-dose maintenance therapy with fluphenazine decanoate. Arch Gen Psychiatry 1987; 44: 518-21.CrossRefGoogle Scholar
Morgenstem, HGlazer, WMNiedzwiecki, DNourjah, P. The impact of neuroleptic medication on tradive diskinesia: a meta-analysis of published studies. Am J Publ Health 1987; 77: 717-24.CrossRefGoogle Scholar
Rosenthal, RRubin, DB. Comparing effect sizes of independent studies. Psychol Bull 1982; 92: 500-4.CrossRefGoogle Scholar
Saraceno, B. Los psicofármacos en una perspectiva de salud publica. Acta Psiquiát Psicol Am Lat 1993; 40: 63-8.Google Scholar
Schooler, NR. Maintenance medication for schizophrenia: strategies of dose reduction. Schizophren Bull 1991; 17: 311-24.CrossRefGoogle ScholarPubMed
Schooler, NR. Reducing dosage in maintenance treatment of schizophrenia. Br J Psychiatry 1993; 163 (suppl 22): 58–65.CrossRefGoogle Scholar
Streiner, DL. Using meta-analysis in psychiatric research. Can J Psychiatry 1991; 36: 357-62.CrossRefGoogle ScholarPubMed
Thacker, SB. Meta-analysis. A quantitative approach to research integration. J Am Med Assoc 1988; 259: 1685–9.CrossRefGoogle ScholarPubMed
Wyatt, R. Neuroleptics and the natural course of schizophrenia. Schizophren Bull 1991; 17: 325-51.CrossRefGoogle ScholarPubMed